Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.40 |
| ▸ | F2R | P25116 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902170 | 0.91 | LMNA (0.44) | LMNAITGB1ITGA4SLC6A9UTS2R | |
| SCHEMBL3903930 | 0.87 | SLC6A9 (0.41) | LMNAITGB1ITGA4SLC6A9UTS2R | |
| SCHEMBL3906111 | 0.87 | UTS2R (0.50) | LMNAITGB1ITGA4SLC6A9UTS2R | |
| SCHEMBL3902029 | 0.85 | ITGB1 (0.43) | LMNAITGB1ITGA4SLC6A9ALDH1A1 | |
| SCHEMBL3901504 | 0.81 | LMNA (0.43) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3901053 | 0.81 | GPR139 (0.49) | LMNAITGB1ITGA4ALDH1A1SMN1; SMN2 | |
| SCHEMBL3906053 | 0.81 | ALDH1A1 (0.57) | LMNAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3907125 | 0.81 | TAS1R3 (0.51) | LMNASLC6A9SMN1; SMN2 | |
| SCHEMBL3901980 | 0.81 | ALDH1A1 (0.47) | LMNAUTS2RALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3907148 | 0.80 | SLC6A9 (0.47) | LMNASLC6A9UTS2RALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838663-B1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LTD (GB) | 2009-01-21 | — | — | EP | claimed |
| US-20090270510-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270510-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270510-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-1838663-B1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LTD (GB) | 2009-01-21 | — | — | EP | disclosed |
| WO-2006067417-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270510-A1 | GLYCINE TRANSPORT INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | LMNA 4455/4885ITGB1 4719/4885ITGA4 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.